Aclaris Therapeutics Dividend
Dividend criteria checks 0/6
Aclaris Therapeutics hat in der Vergangenheit keine Dividende gezahlt.
Key information
n/a
Dividend yield
n/a
Payout ratio
Industry average yield | 2.3% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | n/a |
Earnings per share | -US$1.25 |
Dividend yield forecast in 3Y | n/a |
Recent dividend updates
No updates
Recent updates
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up
Mar 07Analysts Have Been Trimming Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target After Its Latest Report
Mar 01Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jan 19Analysts Are Betting On Aclaris Therapeutics, Inc. (NASDAQ:ACRS) With A Big Upgrade This Week
Nov 11Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Nov 03Analysts Have Lowered Expectations For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Its Latest Results
Aug 10What You Need To Know About The Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Downgrade Today
Aug 08Risks To Shareholder Returns Are Elevated At These Prices For Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
Jun 06We're Hopeful That Aclaris Therapeutics (NASDAQ:ACRS) Will Use Its Cash Wisely
Apr 07Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Dec 21Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions
Oct 06Here's Why We're Not Too Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Situation
Aug 26Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata
Aug 25Aclaris Therapeutics gets a new COO
Aug 01Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
May 28We're Not Very Worried About Aclaris Therapeutics' (NASDAQ:ACRS) Cash Burn Rate
Dec 14Is Aclaris Therapeutics (NASDAQ:ACRS) Using Too Much Debt?
Aug 25Aclaris Therapeutics (ACRS) Investor Presentation - Slideshow
Jun 08Shareholders Will Probably Not Have Any Issues With Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) CEO Compensation
May 28Aclaris Therapeutics EPS misses by $0.29, beats on revenue
May 07Stability and Growth of Payments
Fetching dividends data
Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von ACRS in der Vergangenheit stabil geblieben ist.
Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von ACRS gestiegen sind.
Dividend Yield vs Market
Aclaris Therapeutics Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (ACRS) | n/a |
Market Bottom 25% (US) | 1.5% |
Market Top 25% (US) | 4.7% |
Industry Average (Pharmaceuticals) | 2.3% |
Analyst forecast in 3 Years (ACRS) | n/a |
Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von ACRS im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.
Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von ACRS im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.
Earnings Payout to Shareholders
Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von ACRS, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.
Cash Payout to Shareholders
Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da ACRS keine Ausschüttungen gemeldet hat.